A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030.
Datopotamab deruxtecan (Dato-DXd) is a new form of cancer treatment, known as an antibody-drug conjugate, developed with Japanese company Daiichi Sankyo. Trial results showed the drug failed to help late-stage breast cancer patients live longer than standard chemotherapy, in patients who had previously been treated with hormonal therapies, AstraZeneca said on Monday.
AstraZeneca shares fell 1 per cent in early trading in London. Earlier this month, the drug failed to hit a target for overall survival benefits in patients with non-small-cell lung cancer, causing shares to fall nearly 5 per cent.